Adma Biologics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Adma Biologics Inc 's ROA in the second quarter of 2026?
Adma Biologics Inc achieved a return on average assets (ROA) of 26.25 % in its second quarter of 2026, this is above ADMA's average return on assets of -39.53%.
Adma Biologics Inc assets over the 12 months ending in its second quarter of 2026 are valued at $644 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 37 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 148, from total ROA ranking in the first quarter of 2026 at 181.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	22.53 %	30.28 %	34.33 %	45.59 %	48.35 %
Y / Y Net Income Change	10.53 %	68.48 %	-55.87 %	1.45 %	6.73 %
Net Income (TTM) in million	169	165	147	209	209
Return On Assets (TTM)	26.25 %	27.01 %	25.62 %	39.4 %	42.9 %
ADMA's Total Ranking	# 148	# 181	# 103	# 90	# 95
Total Assets (TTM) in million	684	665	656	569	558
Seq. Total Assets Change	2.86 %	1.33 %	15.43 %	1.85 %	9.36 %
Seq. Net Income Change	-16.56 %	-8.2 %	35.55 %	6.46 %	27.19 %

ADMA's 5 Years Annual ROA >> Back to ADMA Management Effectiveness >> Compare ADMA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 8
Sector	# 38
Overall	# 148

Return On Assets Statistics
High	Average	Low
49.22 %	-39.53 %	-148.69 %
(Dec 31 2024)		(Sep 30 2013)

Financial Statements
Adma Biologics Inc 's Assets	$ 684 million	ADMA's Balance sheet
Adma Biologics Inc 's Income	$ 38 million	Quarterly ADMA's Income Statement
ADMA's Income by Division		See ADMA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	34.33 %	48.45 %	-5.53 %	26.14 %	33.02 %
Total Assets in million	656	489	329	348	276
Y / Y Net Income Change	-25.67 %	-	-	-	-
Net Income in million	147	198	-28	-66	-72
Annual Return On Assets	22.38 %	40.45 %	-8.58 %	-18.91 %	-25.94 %

ADMA's 5 Years Annual ROA >> Back to ADMA Management Effectiveness >> Compare ADMA ROA to its Competitors

Comment on ADMA's ROA in the fiscal year ending 2025

In the fiscal year 2025 Adma Biologics Inc 's ROA decreased compared to previous year to 22.38 %, due to deterioration of net income -25.67 % to $146.93 million, from $197.67 million a year ago, as ADMA's assets were $656.45 million.

More Return On Assets Ratios
ADMA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ADMA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ADMA's Competitors
Subscribers only: Roa for Adma Biologics Inc 's Suppliers
Subscribers only: Return On Assets for ADMA's Customers

You may also want to know
ADMA's Roi	ADMA's Inventory Turnover Ratio	ADMA's Growth Rates	ADMA's Dividend Comparisons
	ADMA's Profitability Ratios	ADMA's Asset Turnover Ratio	ADMA's Dividend Growth
ADMA's Roe	ADMA's Valuation Ratios	ADMA's Financial Strength Ratios	ADMA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %

Date modified: 2026-09-11T09:50:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.